SPECIALITY pharmaceuticals firm BTG yesterday reported a fall in first half pre-tax profits to £2.4m from £3.4m the previous year, following an £11.3m loss stemming from its acquisition of Protherics.<br /><br />BTG saw a jump from £30.2m to £47.9m in revenue for the six months ending September 2009. It plans to establish a US sales force to enable it to begin selling two anti-poison medicines, CroFab and DigiFab, directly when the current distribution arrangement ends. BTG saw sales of the two medicines suffer last year due to disruptions in the manufacturing process. <br /><br />BTG chief executive Louise Makin said: “A robust financial performance... a strong cash position and momentum in the pipeline and across the business together mean BTG can look forward to continued progress.” <br /><br />While analysts at KBC Peel Hunt remained optimistic for BTG’s stock, analysts at Piper Jaffray gave the company an overweight rating. BTG shares closed down 9.8p at 183.20.